PaTHway Phase 3 Trial Analysis

24-Hour Urine Calcium (mg/d) by Visit p-value <0.0001 Pathway TRIAL 450 TransCon Placebo 400 p-value² =0.24 24-Hour Urine Calcium (mg/d), Change from baseline at Week 26 PTH (N = 61) (N = 21) 350 ANCOVA Model (n) 1 300 24-Hour Urine LS Mean (SE), mg/d 250 Calcium (mg/d) Mean (± SE) 200 95% CI for LS Mean 150 100 Difference in LS Means (SE) 95% CI for Difference in LS Means -154 (21) -64 (32) (-197, -112) (-131,2) -90 (32) (-155,-25) 50 p-value (TransCon PTH vs Placebo) 0.0085 0 Baseline (Week 0) Visit 7 (Week 12) Visit 10 (Week 26) TransCon PTH Placebo 1 The ANCOVA model with unequal variance includes the change from baseline as the response variable, treatment and etiology of HP as fixed effects and baseline value of the parameter as a covariate. 2 p-values from t-test. 25 Data on file, Ascendis Pharma 2022. TransCon PTH is an investigational product candidate. For investor communication only. Not for use in product promotion. Not for further distribution. ascendis pharma

View entire presentation